These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 31612822)

  • 1. Nanoparticle-Mediated Drug Delivery: Blood-Brain Barrier as the Main Obstacle to Treating Infectious Diseases in CNS.
    Gondim BLC; da Silva Catarino J; de Sousa MAD; de Oliveira Silva M; Lemes MR; de Carvalho-Costa TM; de Lima Nascimento TR; Machado JR; Rodrigues V; Oliveira CJF; Cançado Castellano LR; da Silva MV
    Curr Pharm Des; 2019; 25(37):3983-3996. PubMed ID: 31612822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically Approved Drugs against CNS Diseases as Potential Therapeutic Agents To Target Brain-Eating Amoebae.
    Anwar A; Rajendran K; Siddiqui R; Raza Shah M; Khan NA
    ACS Chem Neurosci; 2019 Jan; 10(1):658-666. PubMed ID: 30346711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Getting drugs to the brain: advances and prospects of organic nanoparticle delivery systems for assisting drugs to cross the blood-brain barrier.
    Tan Q; Zhao S; Xu T; Wang Q; Lan M; Yan L; Chen X
    J Mater Chem B; 2022 Nov; 10(45):9314-9333. PubMed ID: 36349976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymeric nanoparticles - targeted drug delivery systems for treatment of CNS disorders and their possible endocrine disrupting activities.
    Rollerova E; Scsukova S; Jurcovicova J; Mlynarcikova A; Szabova E; Kovriznych J; Zeljenkova D
    Endocr Regul; 2011 Jan; 45(1):49-60. PubMed ID: 21314211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of Therapeutic Nanoplatforms as a Potential Candidate for the Treatment of CNS Disorders: Challenges and Possibilities.
    Sa P; Singh P; Dilnawaz F; Sahoo SK
    Curr Pharm Des; 2022; 28(33):2742-2757. PubMed ID: 35909283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents.
    Biddlestone-Thorpe L; Marchi N; Guo K; Ghosh C; Janigro D; Valerie K; Yang H
    Adv Drug Deliv Rev; 2012 May; 64(7):605-13. PubMed ID: 22178615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug delivery to the CNS and polymeric nanoparticulate carriers.
    Costantino L
    Future Med Chem; 2010 Nov; 2(11):1681-701. PubMed ID: 21428839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for transporting nanoparticles across the blood-brain barrier.
    Zhang TT; Li W; Meng G; Wang P; Liao W
    Biomater Sci; 2016 Feb; 4(2):219-29. PubMed ID: 26646694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanotechnological advances for the delivery of CNS therapeutics.
    Wong HL; Wu XY; Bendayan R
    Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle enabled drug delivery across the blood brain barrier: in vivo and in vitro models, opportunities and challenges.
    Gidwani M; Singh AV
    Curr Pharm Biotechnol; 2014; 14(14):1201-12. PubMed ID: 24809717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders.
    Guo ZH; Khattak S; Rauf MA; Ansari MA; Alomary MN; Razak S; Yang CY; Wu DD; Ji XY
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concepts, technologies, and practices for drug delivery past the blood-brain barrier to the central nervous system.
    Crawford L; Rosch J; Putnam D
    J Control Release; 2016 Oct; 240():251-266. PubMed ID: 26724368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic approaches of magnetic nanoparticles for the central nervous system.
    Dilnawaz F; Sahoo SK
    Drug Discov Today; 2015 Oct; 20(10):1256-64. PubMed ID: 26103617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Trends in Nanotechnology Toward CNS Diseases: Lipid-Based Nanoparticles and Exosomes for Targeted Therapeutic Delivery.
    Cardoso AM; Guedes JR; Cardoso AL; Morais C; Cunha P; Viegas AT; Costa R; Jurado A; Pedroso de Lima MC
    Int Rev Neurobiol; 2016; 130():1-40. PubMed ID: 27678173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanomedicines for the Treatment of CNS Diseases.
    Reynolds JL; Mahato RI
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):1-5. PubMed ID: 28150132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanobiotechnology-based drug delivery in brain targeting.
    Dinda SC; Pattnaik G
    Curr Pharm Biotechnol; 2013; 14(15):1264-74. PubMed ID: 24910011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hazard effects of nanoparticles in central nervous system: Searching for biocompatible nanomaterials for drug delivery.
    Leite PE; Pereira MR; Granjeiro JM
    Toxicol In Vitro; 2015 Oct; 29(7):1653-60. PubMed ID: 26116398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS.
    Peluffo H; Unzueta U; Negro-Demontel ML; Xu Z; Váquez E; Ferrer-Miralles N; Villaverde A
    Biotechnol Adv; 2015; 33(2):277-87. PubMed ID: 25698504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CNS drug delivery systems: novel approaches.
    Pathan SA; Iqbal Z; Zaidi SM; Talegaonkar S; Vohra D; Jain GK; Azeem A; Jain N; Lalani JR; Khar RK; Ahmad FJ
    Recent Pat Drug Deliv Formul; 2009 Jan; 3(1):71-89. PubMed ID: 19149731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain delivery of antidotes by polymeric nanoparticles.
    Manek E; Petroianu GA
    J Appl Toxicol; 2021 Jan; 41(1):20-32. PubMed ID: 32666582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.